[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
Depo-provera |
|
|
Clinical Trial: Hormonal Contraception and Risk of Chlamydia and Gonorrhea
This study has been terminated.
|
Purpose
There are biological reasons to suspect that hormones may affect the risk of a woman becoming infected with a sexually transmitted disease. The evidence on this issue to date is mixed and previous studies have methodologic flaws making it difficult to draw conclusions about the results.
This study compares the risk of developing either Chlamydial or Gonorrheal infection among three groups of women: those using combined oral contraceptives (birth control pills); those using the injectable hormone (brand name Depo Provera); and those women using non-hormonal contraceptive methods.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Chlamydia Infection Neisseriaceae Infection | Drug: Depo Medroxyprogesterone acetate Drug: Combined oral contraceptives | Phase IV |
MedlinePlus related topics: Bacterial Infections; Chlamydia Infections
Study Type: Observational
Study Design: Natural History, Longitudinal, Defined Population, Prospective Study
Official Title: Hormonal Contraception, Cervical Ectopy, and STDs
Expected Total Enrollment: 1200
Study start: September 1997; Study completion: August 2001
The study was designed to examine the relationship between hormonal contraceptive use and possible increased risk of Chlamydial and Gonococcal sexually transmitted infections, and to determine if any increased risk appeared to be mediated by the extent of cervical ectopy.
Eight hundred and nineteen women, ages 15 to 45 years, were recruited from an inner city clinic and from a nearby suburban clinic. The women were classified into three groups based on type of contraceptive used. One group used oral contraceptives; the second used injectable depo-medroxyprogesterone acetate (DMPA); and the third group used non-hormonal contraceptive methods. Women from each group were followed at 3, 6, and 12 months after enrollment to determine if a new infection with Chlamydia or Gonorhea had occurred and to evaluate the extent of cervical ectopy present.
Eligibility
Ages Eligible for Study: 15 Years - 45 Years, Genders Eligible for Study: Female
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Female age 15 to 45 years
- no hormone use at enrollment
- not pregnant or planning pregnancy
Exclusion Criteria:
Location Information
Charles Morrison, Ph.D., Principal Investigator, Family Health International, RTP, N.C.
Paul Blumenthal, M.D., Principal Investigator, Maryland Planned Parenthood
More Information
Record last reviewed: September 2004
Last Updated: October 13, 2004
Record first received: September 16, 2004
ClinicalTrials.gov Identifier: NCT00091728
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- ¿Que Tipo de Control de La Natalidad Es Mejor Para Usted? (Office for Protection from Research Risks, OD, NIH, HHS)
- Birth Control Guide (Office of Consumer Affairs, OEA, FDA,)

Not Signed In -


